Post‐Viral Aspergillosis: A Systematic Review of Incidence, Clinical Manifestations, and Outcomes
Reviews in Medical Virology · 2026-05 · 36 (3)
DOI: 10.1002/rmv.70163 ↗At a glance
Systematische Übersicht in Reviews in Medical Virology, published online on 2026-06-01. Written by Mandana Akhavan and 7 co-authors. Institution: Division of Molecular Biology, Medical Mycology and Parasitology Department, School of Public Health Research Center, Tehran University of Medical Sc…. Major MEDLINE topics: COVID-19, Aspergillosis, Virus Diseases. 55 references. Funded by: Association Canadienne d'Anthropologie Physique, Association Canadienne d’Anthropologie Physique.
Abstract (original language)
Invasive aspergillosis (IA) has traditionally been associated with immunocompromised individuals. Post‐viral aspergillosis (PVA) has emerged as a significant secondary complication among patients with viral infections, particularly during the COVID‐19 pandemic. This systematic review aimed to summarise the patients' clinical characteristics, diagnostic approaches, treatment options, and outcomes of PVA across various respiratory viral infections. This study was registered in PROSPERO (No. CRD420250652078) and followed the PRISMA 2020 guidelines. We systematically searched PubMed, Embase, Scopus, and Web of Science for publications without a time limitation up to the end of May 2025 reporting clinical data on PVA in patients following infections by respiratory viruses, including SARS‐CoV‐2, influenza, respiratory syncytial virus (RSV), metapneumovirus, parainfluenza, rhinovirus, adenovirus, and cytomegalovirus (CMV). Overall, the reports highlighted PVA occurrence after infections by SARS‐CoV‐2, influenza, and CMV. Our analyses revealed that PVA is a clinically heterogeneous but frequently deadly infection in patients who are critically ill, immunocompromised patients, or those receiving corticosteroids, following respiratory viral infections. Among critically ill patients, PVA is a clinically important complication of respiratory viral infections, and timely diagnosis and early initiation of appropriate antifungal therapy— considering that Aspergillus is an aerobic fungus requiring specific culture conditions—play a key role in improving patient outcomes.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Molecular Biology, Medical Mycology and Parasitology Department, School of Public Health Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- Infectious Diseases Department, Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Biology, McMaster University, Hamilton, Ontario, Canada.
- Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Parasitology and Mycology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
- Center for Communicable Diseases Control (CDC), Ministry of Health and Medical Education, Tehran, Iran.
ORCID profiles: Sadegh Khodavaisy, Maryam Shafaati, Mohammadreza Salehi
Funding
- Association Canadienne d'Anthropologie Physique
- Association Canadienne d’Anthropologie Physique
Cite
APA
Akhavan, M., Khodavaisy, S., Akbarzadeh, S., Mojtahedi, S. S., Xu, J., Aala, F., Shafaati, M., & Salehi, M. (2026). Post‐Viral Aspergillosis: A Systematic Review of Incidence, Clinical Manifestations, and Outcomes. Reviews in Medical Virology, 36(3). https://doi.org/10.1002/rmv.70163
Vancouver
Akhavan M, Khodavaisy S, Akbarzadeh S, Mojtahedi SS, Xu J, Aala F, et al. Post‐Viral Aspergillosis: A Systematic Review of Incidence, Clinical Manifestations, and Outcomes. Reviews in Medical Virology. 2026;36(3). doi:10.1002/rmv.70163
BibTeX
@article{Akhavan2026,
author = {Akhavan, Mandana and Khodavaisy, Sadegh and Akbarzadeh, Saba and Mojtahedi, Seyedeh Sabereh and Xu, Jianping and Aala, Farzad and Shafaati, Maryam and Salehi, Mohammadreza},
title = {Post‐Viral Aspergillosis: A Systematic Review of Incidence, Clinical Manifestations, and Outcomes},
journal = {Reviews in Medical Virology},
year = {2026},
volume = {36},
number = {3},
doi = {10.1002/rmv.70163}
}
EUVIMED